asjenny craig collapsed, the world of weight loss was being revolutionised.drug ozempic was approved to treat diabetes in europe. three years later, the company that makes it, novo nordisk, gained approval in the united states to sell wegovy. wherever you'rejoining us from, welcome to the programme. now, in 1983, a married couple, jenny and sid craig, opened their first weight—loss centre in melbourne, australia. it grew to be a global company with 700 slimming clubs and a food brand so big that nestle bought it for $600 million. well, last year, after changing hands a few more times, jenny craig filed for bankruptcy. all its employees were let go and the brand name was sold once more. asjenny craig collapsed, the world of weight loss was being revolutionised. in 2018, the drug ozempic was approved to treat diabetes in europe. three years later, the company that makes it, novo nordisk, gained approval in the united states to sell wegovy. it's a higher dose of the same ingredient that's in ozempic, but this one would treat obesity. the rush for the drugs was u

asjenny craig collapsed, the world of weight loss was being revolutionised.ic was approved to treat diabetes in europe. three years later, the company that makes it, novo nordisk, gained approval in the united states to sell wegovy. it's a higher dose of the same ingredient that's in ozempic, but this one would treat obesity. the rush for the drugs was unexpected, as one of the bosses of novo nordisk told the bbc earlier this year. this demand in the market for glp—1, both in diabetes and obesity, hasjust stepped up much more than we ever forecasted. and by the way, much more than anyone forecasted. meanwhile, in the united states, a rival suite of drugs from pharmaceutical giant eli lilly were approved. mounjaro, in 2022, to treat diabetes, and zepbound, in 2023, for obesity. novo nordisk has not been fazed by the competition, though. first and foremost, in this industry, when we talk about obesity, then all the market potential is so big that there's more than enough space for two or even more competitors. so that's the starting point. and then, in the phar